drugset / Trial / NCT06941857
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2
Recruiting
20 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lustgarten Foundation · collabNextCure, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Timeline
- Start
- 2025-09-04
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 50 mg | Intravenous |
| Subject | NC410 | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Oxaliplatin | Small molecule | 65 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |